SuperworthRepligen market cap RGEN
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $10B
- Highest close in our data
- $17.8B
- Sep 2021
Repligen is worth $10B at the close on Oct 23, 2026, at $176.93 a share.
That is up 7% over the last year and down 38% over five years.
Its highest close in our data was $17.8B in Sep 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $10B | $5.8B | $10.7B | +7% |
| 2025 | $9.4B | $6.3B | $9.6B | +15% |
| 2024 | $8.2B | $6.7B | $11.6B | −19% |
| 2023 | $10B | $6.7B | $10.8B | +7% |
| 2022 | $9.4B | $7.9B | $13.9B | −36% |
| 2021 | $14.6B | $9.4B | $17.8B | +45% |
| 2020 | $10.1B | $4.5B | $10.8B | +110% |
| 2019 | $4.8B | $2.2B | $4.8B | +113% |
| 2018 | $2.3B | $1.3B | $3B | +42% |
| 2017 | $1.6B | $983.8M | $1.7B | +52% |
| 2016 | $1B | $693.1M | $1.1B | +12% |
| 2015 | $932M | $657.7M | $1.4B | +41% |
| 2014 | $662.3M | $397.6M | $823.4M | +64% |
| 2013 | $404M | $195.4M | $429.8M | +114% |
| 2012 | $189.2M | $106M | $200.7M | +77% |
| 2011 | $106.6M | $96.8M | $108.2M | n/a |
Against its peers
Companies in Biotechnology nearest Repligen's size, closest first, today.
| Company | Market cap |
|---|---|
| RGENRepligen | $10B |
| KRYSKrystal Biotech | $9.2B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| UTHRUnited Therapeutics | $25.2B |
| ALNYAlnylam Pharmaceuticals | $30B |
| ADMAAdma Biologics | $2.4B |
| ONCBeOne Medicines | $42.9B |
| Peer median | $15.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Repligen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.